Key Developments: Bristol-Myers Squibb Co (BMY)
46.78USD
23 May 2013
$0.38 (+0.82%)
$46.40
$46.18
$47.22
$45.87
6,057,541
10,313,134
$47.48
$30.64
Latest Key Developments (Source: Significant Developments)
Reckitt Benckiser Group Plc Announces Completion Of Latam Otc Collaboration Agreement With Bristol-Myers Squibb Company
Reckitt Benckiser Group Plc announced that the three year collaboration agreement signed with Bristol-Myers Squibb Company on February 10, 2013 has been completed and that regulatory approvals, including anti-trust approvals in the relevant jurisdictions, have now been obtained. The terms of the agreement include the transfer of personnel, supply contracts and an option to acquire legal title to the related intellectual property at the end of the collaboration period, based on business performance. Reckitt Benckiser will account for the transaction as a business combination. Full Article
Bristol-Myers Squibb Co Receives US FDA sNDA Approval For Use Of SUSTIVA (efavirenz) In HIV-1 Infected Pediatric Patients
Bristol-Myers Squibb Co announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg. This approval offers a once-daily option as part of a regimen for this population and includes a capsule sprinkle administration method for patients who cannot swallow capsules or tablets. This sNDA was based on results from three open-label studies that evaluated the pharmacokinetics, safety, and antiretroviral activity of SUSTIVA in combination with other antiretroviral agents in 182 antiretroviral-naïve and -experienced HIV-1 infected pediatric patients (three months to 21 years of age) for a median of 123 weeks. Virologic and immunologic response was observed across all ages at the end of the studies, as measured by HIV RNA and CD4 cell count. The adverse reactions observed in the three pediatric trials were similar to those observed in clinical trials in adults, except that rash was more common in pediatric patients (32% for all grades regardless of causality) and more often of higher grade (i.e., more severe). Five pediatric patients (2.7%) discontinued from the study because of rash. Full Article
Bristol-Myers Squibb Co Reaffirms FY 2013 EPS Guidance
Bristol-Myers Squibb Co announced that for fiscal 2013, it confirms GAAP EPS guidance range of $1.54 to $1.64 and its non-GAAP EPS guidance range of $1.78 to $1.88. Both GAAP and non-GAAP guidance assume current exchange rates. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $1.83 for fiscal 2013. Full Article
Bristol-Myers Squibb Co Announces Worldwide Discovery Alliance With Santaris Pharma A/S For RNA-Targeted Medicines
Bristol-Myers Squibb Co announced a worldwide strategic alliance with Santaris Pharma A/S, to discover and develop medicines using Santaris Pharma's Locked Nucleic Acid (LNA) Drug Platform. Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10 million, up to $90 million in potential payments per product and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance. Full Article
AstraZeneca PLC and Bristol-Myers Squibb Co Complete Acquisition of Rights for Byetta and Bydureon from Eli Lilly And Co
AstraZeneca PLC and Bristol-Myers Squibb Co announced that they completed the acquisition of rights to Byetta (exenatide) and Bydureon (exenatide) from Eli Lilly And Co. AstraZeneca and Bristol-Myers Squibb started in January 2007 a diabetes alliance and a cooperation on research, development and sale for certain products for type 2 diabetes. Full Article
Bristol-Myers Squibb Co's and Sanofi SA's Plavix to Be Investigated by U.S. Department of Justice-Reuters
Reuters reported that Sanofi SA announced that the U.S. Department of Justice (DoJ) is investigating disclosures to the Food & Drug Administration (FDA) about the variable response that certain patients may have to blood-thinner Plavix. The Company announced in its annual report it became aware of the probe in June 2012 and was cooperating with the DoJ. Plavix was co-marketed by Sanofi SA and Bristol-Myers Squibb Co before it lost patent protection in May 2012. The U.S. FDA added a so-called boxed warning to Plavix in 2010 to highlight that the drug could be less effective in certain patients who could not metabolize it properly. The Company's spokeswoman declined to comment on the probe. Full Article
Bristol-Myers Squibb Co Announces Dividend
Bristol-Myers Squibb Co announced that its Board of Directors declared a quarterly dividend of $0.35 per share on the $0.10 par value Common Stock of the corporation. The quarterly dividend will be payable on May 1, 2013, to stockholders of record at the close of business on April 5, 2013. The Directors also declared a quarterly dividend of $0.50)per share on the $2.00 Convertible Preferred Stock of the corporation, payable June 3, 2013, to stockholders of record at the close of business on May 10, 2013. Full Article
Reckitt Benckiser Group Plc Signs Three Year Collaboration Agreement With Bristol-Myers Squibb Co
Reckitt Benckiser Group Plc announced that it has signed a three year collaboration agreement with Bristol-Myers Squibb (BMS) for a number of over-the-counter (OTC) consumer health care brands in Brazil, Mexico and certain other parts of Latin America (collectively BMS Assets), with an option to purchase at the end of the three year period. The key brands included under the agreement are: Naldecon, Luftal, Dermodex from brazil; Tempra, Picot and Graneodin-B from Mexico. Under this collaboration, RB will licence the brands from BMS, who will continue to manufacture them for three years. Under the terms of the agreement RB will initially pay BMS $482 million to enter into the arrangement which also includes personnel, supply contracts and an option to acquire legal title to the related intellectual property at the end of the collaboration period, based on business performance. The transaction will be accounted for as a business combination and the Directors are in the process of revaluing the assets and liabilities acquired to fair value, including the value of any acquired intangible assets. Under the terms of a separate supply agreement BMS will be RB's supplier of the products during the collaboration period. Full Article
Bristol-Myers Squibb Co Seeking Buyer For Mexico, Brazil Brands-Reuters
Reuters reported that Bristol-Myers Squibb Co is seeking a buyer for some of its brands in Mexico and Brazil with any sale possible bringing in as much as $750 million, the Wall Street Journal reported, citing people familiar with the matter. A small number of U.S. and European drug and consumer companies are still bidding for the brands and a deal could materialize as early as the next two to three weeks, the Journal said. Full Article
UK Cost Agency Rejects Drugs From Bristol-Myers Squibb Co, Roche Holding AG And AstraZeneca PLC-Reuters
Reuters reported that Britain's healthcare cost watchdog NICE said on February 01, 2013 it was not able to recommend a new diabetes drug from Bristol-Myers Squibb Co and AstraZeneca PLC, and has asked for more information from the companies. The National Institute for Health and Clinical Excellence (NICE) has been considering Forxiga, or dapagliflozin, as an add-on therapy for use with other medicines, including insulin. NICE, which decides if drugs should be paid for on the state health service, also said it had issued draft guidance not recommending Roche Holding AG's Avastin for ovarian cancer. The agency has already rejected Avastin in other tumour types. Full Article
Bristol melanoma drug combo marks new advance in immunotherapy
CHICAGO - Melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for treatments that harness the body's immune system to fight cancer.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
